References 1. Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R, et al. (2001) Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19: 1732–1737. 2. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354: 1343–1351. 3. Treanor JJ, Kotloff K, Betts RF, Belshe R, Newman F, et al. (1999) Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 18: 899–906. 4. Belshe RB, Gruber WC, Mendelman PM, Cho I, Reisinger K, et al. (2000) Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 136: 168–175. 5. Karron RA, Talaat K, Luke C, Callahan K, Thumar B, et al. (2009) Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 27: 4953–4960. 6. van Riel D, den Bakker MA, Leijten LM, Chutinimitkul S, Munster VJ, et al. (2007) Seasonal and pandemic human influenza viruses attach better to human upper respiratory tract epithelium than avian influenza viruses. Am J Pathol 176: 1614–1618. 7. Suzuki Y (2005) Sialobiology of influenza: molecular mechanism of host range variation of influenza viruses. Biol Pharm Bull 28: 399–408. 8. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, et al. (2006) Avian flu: influenza virus receptors in the human airway. Nature 440: 435–436. 9. Nicholls JM, Chan MC, Chan WY, Wong HK, Cheung CY, et al. (2007) Tropism of avian influenza A (H5N1) in the upper and lower respiratory tract. Nat Med 13: 147–149. 10. Desheva JA, Lu XH, Rekstin AR, Rudenko LG, Swayne DE, et al. (2006) Characterization of an influenza A H5N2 reassortant as a candidate for live- attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. Vaccine 24: 6859–6866. 11. Rudenko L, Desheva J, Korovkin S, Mironov A, Rekstin A, et al. (2008) Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I-II clinical trials). Influenza Other Respi Viruses 2: 203–209. 12. Washington N, Steele RJ, Jackson SJ, Bush D, Mason J, et al. (2000) Determination of baseline human nasal pH and the effect of intranasally administered buffers. Int J Pharm 198: 139–146. 13. McShane D, Davies JC, Davies MG, Bush A, Geddes DM, et al. (2003) Airway surface pH in subjects with cystic fibrosis. Eur Respir J 21: 37–42. 14. England RJ, Homer JJ, Knight LC, Ell SR (1999) Nasal pH measurement: a reliable and repeatable parameter. Clin Otolaryngol Allied Sci 24: 67–68. 15. Hehar SS, Mason JD, Stephen AB, Washington N, Jones NS, et al. (1999) Twenty-four hour ambulatory nasal pH monitoring. Clin Otolaryngol Allied Sci 24: 24–25. 16. Carr CM, Chaudhry C, Kim PS (1997) Influenza hemagglutinin is spring-loaded by a metastable native conformation. Proc Natl Acad Sci U S A 94: 14306–14313. 17. Skehel JJ, Wiley DC (2000) Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 69: 531–569. 18. Scholtissek C (1985) Stability of infectious influenza A viruses at low pH and at elevated temperature. Vaccine 3: 215–218. 19. Reed ML, Bridges OA, Seiler P, Kim JK, Yen HL, et al. (2009) The pH of activation of the hemagglutinin protein regulates H5N1 influenza virus pathogenicity and transmissibility in ducks. J Virol 84: 1527–1535. 20. Romanova J, Krenn BM, Wolschek M, Ferko B, Romanovskaja-Romanko E, et al. (2009) Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine. PLoS One 4: e5984. 21. Reed ML, Yen HL, DuBois RM, Bridges OA, Salomon R, et al. (2009) Amino acid residues in the fusion peptide pocket regulate the pH of activation of the H5N1 influenza virus hemagglutinin protein. J Virol 83: 3568–3580. 22. Fischer H, Widdicombe JH (2006) Mechanisms of acid and base secretion by the airway epithelium. J Membr Biol 211: 139–150. 23. Ilyushina NA, Govorkova EA, Russell CJ, Hoffmann E, Webster RG (2007) Contribution of H7 haemagglutinin to amantadine resistance and infectivity of influenza virus. J Gen Virol 88: 1266–1274. 24. Di Trani L, Savarino A, Campitelli L, Norelli S, Puzelli S, et al. (2007) Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses. Virol J 4: 39. 25. Horimoto T, Takada A, Fujii K, Goto H, Hatta M, et al. (2006) The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate. Vaccine 24: 3669–3676. Increased Infectivity of H5N1 Influenza Virus 26. Tellier R (2009) Aerosol transmission of influenza A virus: a review of new studies. J R Soc Interface 6(Suppl 6): S783–790. 27. Scholtissek C (1985) Stability of infectious influenza A viruses to treatment at low pH and heating. Arch Virol 85: 1–11. 28. Lin YP, Wharton SA, Martin J, Skehel JJ, Wiley DC, et al. (1997) Adaptation of egg-grown and transfectant influenza viruses for growth in mammalian cells: selection of hemagglutinin mutants with elevated pH of membrane fusion. Virology 233: 402–410. 29. Wacheck V, Egorov A, Groiss F, Pfeiffer A, Fuereder T, et al. (2010) A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. J Infect Dis 201: 354–362. 30. Nakowitsch SWM, Morokutti A, Ruthsatz T, Krenn B, Ferko B, Ferstl N, Triendl A, Muster T, Egorov A, Romanova J (2011) Mutations affecting the stability of the haemagglutinin molecule impair the immunogenicity of H3N2 DNS1 intranasal influenza vaccine candidates. Vaccine. In press. 31. Wine JJ, Joo NS (2004) Submucosal glands and airway defense. Proc Am Thorac Soc 1: 47–53. 32. Grubb BR, Boucher RC (1999) Pathophysiology of gene-targeted mouse models for cystic fibrosis. Physiol Rev 79: S193–214. 33. Limberis M, Anson DS, Fuller M, Parsons DW (2002) Recovery of airway cystic fibrosis transmembrane conductance regulator function in mice with cystic fibrosis after single-dose lentivirus-mediated gene transfer. Hum Gene Ther 13: 1961–1970. 34. Fischer H, Widdicombe JH, Illek B (2002) Acid secretion and proton conductance in human airway epithelium. Am J Physiol Cell Physiol 282: C736–743. 35. Steinhauer DA, Wharton SA, Skehel JJ, Wiley DC, Hay AJ (1991) Amantadine selection of a mutant influenza virus containing an acid-stable hemagglutinin glycoprotein: evidence for virus-specific regulation of the pH of glycoprotein transport vesicles. Proc Natl Acad Sci U S A 88: 11525–11529. 36. Takeuchi K, Lamb RA (1994) Influenza virus M2 protein ion channel activity stabilizes the native form of fowl plague virus hemagglutinin during intracellular transport. J Virol 68: 911–919. 37. Cyranoski D (2005) China’s chicken farmers under fire for antiviral abuse. Nature 435: 1009. 38. Brown JD, Goekjian G, Poulson R, Valeika S, Stallknecht DE (2009) Avian influenza virus in water: infectivity is dependent on pH, salinity and temperature. Vet Microbiol 136: 20–26. 39. Sturm-Ramirez KM, Hulse-Post DJ, Govorkova EA, Humberd J, Seiler P, et al. (2005) Are ducks contributing to the endemicity of highly pathogenic H5N1 influenza virus in Asia? J Virol 79: 11269–11279. 40. Hatta M, Hatta Y, Kim JH, Watanabe S, Shinya K, et al. (2007) Growth of H5N1 influenza A viruses in the upper respiratory tracts of mice. PLoS Pathog 3: 1374–1379. 41. Thompson CI, Barclay WS, Zambon MC, Pickles RJ (2006) Infection of human airway epithelium by human and avian strains of influenza a virus. J Virol 80: 8060–8068. 42. Gabriel G, Herwig A, Klenk HD (2008) Interaction of polymerase subunit PB2 and NP with importin alpha1 is a determinant of host range of influenza A virus. PLoS Pathog 4: e11. 43. Scull MA, Gillim-Ross L, Santos C, Roberts KL, Bordonali E, et al. (2009) Avian Influenza virus glycoproteins restrict virus replication and spread through human airway epithelium at temperatures of the proximal airways. PLoS Pathog 5: e1000424. 44. Steel J, Lowen AC, Mubareka S, Palese P (2009) Transmission of influenza virus in a mammalian host is increased by PB2 amino acids 627K or 627E/701N. PLoS Pathog 5: e1000252. 45. Salomon R, Franks J, Govorkova EA, Ilyushina NA, Yen HL, et al. (2006) The polymerase complex genes contribute to the high virulence of the human H5N1 influenza virus isolate A/Vietnam/1203/04. J Exp Med 203: 689–697. 46. Reed LJ, Muench H (1938) A simple method for estimating fifity percent endpoints. Am J Hyg 27: 493–497. 47. Lorenz RJ, Bogel K (1973) Laboratory techniques in rabies: methods of calculation. Monogr Ser World Health Organ. pp 321–335. 48. Ferko B, Kittel C, Romanova J, Sereinig S, Katinger H, et al. (2006) Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts. J Virol 80: 11621–11627. 49. Muster T, Ferko B, Klima A, Purtscher M, Trkola A, et al. (1995) Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus. J Virol 69: 6678–6686. PLoS ONE | www.plosone.org 12 April 2011 | Volume 6 | Issue 4 | e18577